Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus trastuzumab emtansine versus placebo plus trastuzumab emtansine as adjuvant therapy in high-risk HER2-positive early breast cancer after neoadjuvant treatment
CTR20211246Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, trastuzumab emtansine in breast cancer, sponsored by Roche. Started Aug 2021; status: active.
02
Drugs
atezolizumabtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211246.